Show simple item record

dc.contributor.authorMeeks, J
dc.contributor.authorBellmunt, J
dc.contributor.authorBochner, B
dc.contributor.authorClarke, Noel W
dc.contributor.authorDaneshmand, S
dc.contributor.authorGalsky, M
dc.contributor.authorHahn, N
dc.contributor.authorLerner, S
dc.contributor.authorMason, M
dc.contributor.authorPowles, T
dc.contributor.authorSternberg, C
dc.contributor.authorSonpavde, G
dc.date.accessioned2012-12-05T16:48:21Z
dc.date.available2012-12-05T16:48:21Z
dc.date.issued2012-09
dc.identifier.citationA systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. 2012, 62 (3):523-33 Eur Urolen_GB
dc.identifier.issn1873-7560
dc.identifier.pmid22677572
dc.identifier.doi10.1016/j.eururo.2012.05.048
dc.identifier.urihttp://hdl.handle.net/10541/254591
dc.description.abstractMuscle-invasive bladder cancer (MIBC) is a disease with a pattern of predominantly distant and early recurrences. Neoadjuvant cisplatin-based combination chemotherapy has demonstrated improved outcomes for MIBC.
dc.language.isoenen
dc.rightsArchived with thanks to European urologyen_GB
dc.titleA systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.en_GB
dc.identifier.journalEuropean Urologyen_GB
html.description.abstractMuscle-invasive bladder cancer (MIBC) is a disease with a pattern of predominantly distant and early recurrences. Neoadjuvant cisplatin-based combination chemotherapy has demonstrated improved outcomes for MIBC.


Files in this item

This item appears in the following Collection(s)

Show simple item record